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Abstract
Background:  Chronic human immunodeficiency virus (HIV) infection is associated with an
increased incidence of Non-Acquired Immunodeficiency Syndrome (non-AIDS) defining cancers.
To date, only a limited number of cases of bladder cancer have been linked with HIV infection. We
sought to describe the clinical characteristics of HIV-associated bladder cancer.
Methods: A retrospective study was performed involving HIV-positive patients with bladder
cancer, combining cases from multiple institutions with published case reports. Data regarding
patient demographics, HIV status, clinical presentation, pathology, cancer treatment, and outcome
were analyzed using descriptive statistics.
Results: Eleven patients were identified with a median age of 55 years (range, 33 - 67). The median
CD4+ count at cancer diagnosis was 280 cells/mm3 (range, 106 - 572 cells/mm3). Six patients (55%)
had a known risk factor for bladder cancer, and nine (82%) presented with hematuria. Ten patients
had transitional cell carcinoma, and most had superficial disease at presentation. Treatment
included mainly transurethral resection of bladder tumor followed by a combination of local and
systemic therapies. One patient received intravesical bacillus Calmette-Guèrin (BCG) without
complication. Several patients (55%) were alive following therapy, although many (64%) suffered
from local relapse and metastatic disease.
Conclusion: Bladder cancer is part of the growing list of cancers that may be encountered in
patients living longer with chronic HIV-infection. Our patients presented at a younger age and with
only mild immunosuppression, however, they experienced an expected course for their bladder
cancer. Hematuria in an HIV-infected patient warrants a complete evaluation.
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Background
Human immunodeficiency virus (HIV) infection has
become a chronic illness for many patients since the
advent of highly active antiretroviral therapy (HAART). As
their life expectancy increases, patients with chronic HIV
infection are developing diseases associated with aging
and longer-term exposure to several oncogenic risk factors
(e.g. oncovirus coinfection). Specifically, epidemiologic
studies in the HAART era have demonstrated an increased
incidence of Non-AIDS Defining Cancers (NADC) includ-
ing lung cancer, skin cancer (other than Kaposi sarcoma),
anal cancer, hepatocellular carcinoma, conjunctival can-
cer, Hodgkin lymphoma, plasma cell neoplasia and leio-
myosarcoma in HIV-infected patients [1]. Several factors
likely contribute to the development of NADC in this
population such as family history, exposure to oncovi-
ruses including human papilloma virus (HPV) and
Epstein-Barr Virus (EBV), and tobacco consumption
(chewing or smoking). However, HIV-mediated immuno-
suppression, per se, appears to play a lesser role in car-
cinogenesis than has been reported with classic AIDS-
defining tumors (Kaposi sarcoma, non-Hodgkin lym-
phoma, and cervical cancer). While HIV infection may not
lead to an increased incidence of all malignancies, it can
alter the presentation, natural history and potential thera-
peutic options available to patients afflicted with these
neoplasms.
Bladder cancer has been reported in association with HIV
infection in a limited number (six) of published case
reports [2-6]. Large epidemiologic studies conflict on
whether there is an increased incidence of bladder cancer
in the HIV-infected population. In a study from Zambia
(1980-1989), involving 7836 cases of neoplasia, bladder
carcinoma (6.3%) was the third leading malignancy
reported, after carcinoma of the cervix (19.6%) and
Kaposi's sarcoma (7%) [7]. However, a review of the can-
cer registry of Uganda for incidence rates from 1989 to
1991 showed a decline in the incidence of bladder cancer
with the emergence of AIDS-related Kaposi sarcoma [8].
Linked population-based AIDS and cancer registry data
(1978-1996) from the United States, including 302,834
adults with HIV/AIDS, identified 48 people with HIV-
associated bladder cancer with a relative risk of approxi-
mately 0.6 in this group compared to the general popula-
tion [9]. A 2007 meta-analysis of several studies involving
444,172 individuals with HIV/AIDS did not demonstrate
an increased incidence of bladder cancer in the HIV pop-
ulation compared to the general population [10]. Most
recently, a 2008 epidemiologic study using HIV/AIDS
Cancer Match Study data reported a lower incidence of
bladder cancer in the HIV population as compared to the
general population with a standardized incidence ratio of
0.7 [11].
To date, there have been no published series that specifi-
cally address the association and management issues
related to bladder cancer in the setting of HIV-infection.
Therefore, the aim of this study was to investigate a series
of HIV-associated bladder cancer cases, together with
cases previously published in the literature, and to iden-
tify particular risk factors, clinical findings, pathologic fea-
tures, management issues, and/or response to therapy in
this group of immunocompromised patients.
Methods
Following institutional review board approval, we per-
formed a retrospective, multi-institutional study involv-
ing HIV positive patients with concomitant bladder
cancer. Cases were identified from the personal archives
of the authors for patients with a combined diagnosis of
HIV infection and confirmed bladder carcinoma. The lit-
erature was searched for additional cases using PubMed
and previous article reference lists for all published cases
in the English and Non-English literature. We extracted
data from the medical records and published papers
which included patient demographics (age, gender), HIV
status (CD4+ cell count, HIV viral load), clinical presenta-
tion, pathology (carcinoma histological subtype and
grade according to WHO), cancer treatment, and out-
come. Accrued data were analyzed using descriptive statis-
tics.
Results
We identified 11 patients with confirmed HIV-associated
bladder carcinoma; 5 from the authors' personal archives
(labeled case 1 through to 5) over a 5-year period (2001-
2006) and 6 published reports (1992-2002) from Spain,
Italy, Germany, and Qatar [2-6]. The details of this patient
cohort are summarized in Table 1.
Clinical Findings
The median patient age was 55 years (range, 33 - 67
years), and the majority were male (M:F 9:2). Five patients
were Caucasian and one was Hispanic. The race of the
other six patients was not reported. Ten patients (91%)
had known HIV infection at the time of their bladder can-
cer diagnosis, and the eleventh patient was diagnosed
with HIV and bladder cancer concurrently. The median
CD4+ cell count was 280 cells/mm3 (range, 106 - 572
cells/mm3). An HIV viral load was available in seven of
the cases; mean HIV viral load was 102,400 copies/ml
(range, <50 to 665,000 copies/mL). The mean reported
duration of HIV infection prior to the development of
bladder cancer was 8 years (range, 1-25 years). A total of
six (55%) patients were on HAART at the time of diagno-
sis of their bladder malignancy and one initiated HAART
upon starting cancer treatment. Two of the patients were
on trimethoprim-sulfamethoxazole prophylaxis. Compli-
ance with taking antiretroviral medication and HIV resist-B
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Table 1: Characteristics of patients with HIV-associated bladder cancer.
Case Age
(years)
Gender CD4 count 
(cells/mm3)
HIV load 
(copies/mL)
HAART Clinical 
Presentation
Pathology TNM (stage)
at diagnosis
Therapy Outcome
Al Soub2
1992
49 Male 270 NR AZT only* Frequency, 
Dysuria,
LAP
TCC
LG
T1N0M0
(stage I)
Radiation
TURBT
Alive 1 year later
Clemente Ramos et al3
1998
33 Male 106 NR AZT only Frequency, 
Dysuria, 
Hematuria
Weight loss
TCC
HG
NR Surgery
Systemic 
chemotherapy
Died 5 months after diagnosis
Wolf4
2001
37 Female 318 NR No Hematuria,
LAP
TCC
HG
T1N0M0
(stage I)
TURBT
Radiation
Alive
Santos et al5 2002 51 Male 228 NR NR NR SCC NR NR Alive 4 months later
Manfredi et al6
2000
58 Male 572 1,600 Yes Hematuria TCC
LG
TaN0M0
(stage 0a)
TURBT Relapsed with local disease, Alive
Manfredi et al6
2002
57 Male 447 665,000 Yes Hematuria TCC
HG
T1N0M0
(stage I)
TURBT
Local 
chemotherapy
Cystectomy
Relapsed with local disease, Alive 8 
months later
Case 1 61 Male 228 <50 Yes Hematuria TCC
HG
Papillary
T1N0M0
(stage I)
TURBT
Local 
chemotherapy
Palliative surgery 
and radiation
Relapsed with metastatic disease, Died 
7 months later
Case 2 49 Male 280 <50 Yes Frequency, 
Urgency,
Dysuria, 
Hematuria
TCC
HG
TaN0M0
(stage 0a)
TURBT
Local 
chemotherapy
Cystectomy
Multiple local relapses, Alive 1 year 
later
Case 3 63 Male 317 50,000 Yes Hematuria TCC
HG
T3N2M1
(stage IV)
TURBT
Systemic 
chemotherapy
Died within 6 months
Case 4 55 Male 280 <50 Yes* Hematuria TCC
HG
T1N0M0
(stage I)
TURBT
Cystectomy
Radiation
Craniotomy
Relapsed with metastatic disease, Died 
3 years after diagnosis
Case 5 67 Female 445 <50 Yes Hematuria,
LAP
TCC
HG
T4N0M0
(stage IV)
Palliative 
radiation
Embolization of 
one vesical artery
NR
NR = Not reported; LAP = lower abdominal pain; TCC = Transitional cell carcinoma; SCC = Squamous cell carcinoma; HG = High grade; LG = Low grade; AZT = zidovudine; * = started after 
bladder cancer diagnosis; HAART = highly active antiretroviral therapy; TURBT = transurethral resection of bladder tumorBMC Urology 2009, 9:10 http://www.biomedcentral.com/1471-2490/9/10
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ance data were not available for most cases, but two
patients had known poor compliance with HAART ther-
apy. One patient (case 1) had stopped his antiretrovirals
for three months prior to the incidental presentation with
microscopic hematuria on routine urinalysis. Two case
reports from the literature described patients diagnosed
with bladder cancer prior to the advent of HAART therapy
[2,3]. Both of these patients were treated with zidovudine
monotherapy around the time of their cancer treatment.
In general, this cohort did not suffer from multiple medi-
cal co-morbidities or opportunistic infections. A single
patient had a history of both Kaposi sarcoma and oral
candidiasis. Three patients had hepatitis C co-infection
and one had both hepatitis B and hepatitis C co-infection.
Two patients were actively using intravenous drugs and
two patients had hypertension. One patient had a history
of cervical cancer treated with radiation therapy, which
developed decades prior to HIV and bladder cancer diag-
noses.
Six (55%) patients had at least one known risk factor for
the development of bladder cancer. Five (45%) had a his-
tory of smoking, and one patient had previous pelvic radi-
ation therapy. Two patients suffered from recurrent
cystitis, and three had a history of genitourinary calculi.
One patient had recurrent urinary tract infections as a
result of radiation cystitis and small bladder volume from
pelvic radiation. Another patient had recurrent urinary
tract infections associated with a history of bladder stones
(including indinavir-related stones). There were no
reported occupational or other chemical exposures in this
group of patients. Also, no patient had a reported history
of significant analgesic use, exposure to chemotherapeutic
agents (i.e. cyclophosphamide) or a family history of
bladder cancer.
All ten patients with a reported clinical presentation had
signs or symptoms which led to the diagnosis of bladder
cancer. Nine (82%) patients presented with hematuria,
and in five cases this was the only presenting sign. Micro-
scopic hematuria was identified in four patients, inciden-
tally in two cases, and during evaluation for urinary
symptoms in another two cases. Five patients presented
with or developed gross hematuria with blood clots,
including two patients who initially had microscopic
hematuria. Three patients (27%) had lower abdominal
pain on presentation and four (36%) complained of irri-
tative symptoms such as frequency, urgency and/or dysu-
ria. One individual had notable weight loss and was
found on physical examination to have a large mass
invading the anterior vaginal wall.
The radiologic and urologic evaluation of the urinary
symptoms involved several modalities including urine
cytology, ultrasound, intravenous pyelogram (IVP), com-
puterized tomography (CT) scans and cystoscopy. The
diagnostic tests used in these patients varied based on
available technology at the time of diagnosis and degree
of symptoms. Three patients had urine cytology for initial
evaluation, and only one had a positive result. Two
patients underwent IVP, and one study was positive for a
large filling defect and a bladder calculus, and the other
did not demonstrate any abnormalities. Ultrasound of the
urinary system was the initial test in three patients, includ-
ing two patients with incidental microscopic hematuria.
This modality suggested a muscle-invading bladder tumor
in one patient, bilateral nephrolithiasis in one patient and
was normal in the third patient. CT scans, including the
CT-urogram technique, was used in seven patients for
evaluation of symptoms and/or for staging [2,3,6]. Blad-
der wall thickening and hydronephrosis were the most
common abnormalities identified. Three patients were
found to have locally invasive or metastatic disease by CT
scan (Figures 1 and 2).
Ultimately, all ten patients underwent cystoscopy for tis-
sue diagnosis and local tumor management. Most
patients had papillary masses identified, but one patient
had a sessile tumor involving most of his bladder wall [3].
Three patients had grossly necrotic tissue visible and one
patient had tumor completely filling the bladder. The
patient with a history of pelvic radiation was found to
have a necrotic, calcified posterior bladder wall, and ran-
dom biopsies demonstrated bladder cancer. Two patients
had multifocal papillary tumors on initial cystoscopy, one
with a papillary tumor visible in the prostatic urethra. Two
patients had stones (seen previously on imaging) in the
bladder [2].
Pathologic Features
Most cases (10/11) had transitional cell carcinoma (TCC;
also referred to as urothelial carcinoma) that was high
grade in eight and low grade in two individuals. In four of
these cases a papillary architecture (i.e. papillary TCC) was
reported. Three patients had necrotic tumors at presenta-
tion. One patient (case 1) with recurrent tumors, had neu-
roendocrine features identified on pathology (Figure 3).
There was only one case of squamous cell carcinoma
(SCC). There was sufficient data for TNM staging at the
time of bladder cancer diagnosis in 9 cases. The tumor was
non-invasive (Ta) in two patients, invaded the subepithe-
lial urinary bladder connective tissue in five (56%) cases
(Figure 4), and the perivesical tissue (T3) in one individ-
ual. One person had stage T4 disease as a result of tumor
invasion into the vaginal wall. Only one patient had iden-
tifiable lymph node (N2) involvement and concomitant
distant (M1) metastases at initial presentation. At the time
of bladder cancer presentation, two patients had stage Ta
disease, five had stage I disease, and two had stage IV dis-BMC Urology 2009, 9:10 http://www.biomedcentral.com/1471-2490/9/10
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ease. Three patients had metastatic disease during their
course and the sites of involvement included bone, brain
and regional lymph nodes. In one case (case 2), following
radial cystoprostatectomy prostatic adenocarcinoma of
Gleason grade 3 + 3 = 6/10 was discovered incidentally
involving approximately 5% of prostatic volume. In
another case, prostatic intraepithelial neoplasia was iden-
tified.
Patient Management
Information regarding treatment was available in 10
cases. Transurethral resection of bladder tumor (TURBT)
was performed in eight cases, including all cases of super-
ficial disease. Five patients required repeat TURBT because
of relapsed disease. Three patients with T1 disease were
given intravesical chemotherapy following surgical resec-
tion. Each received at least one cycle of mitomycin C, with
one patient receiving five cycles of this therapy. One
patient was given a cycle of intravesical epirubicin and
another was given intravesical bacillus Calmette-Guèrin
(BCG), both following relapse after mitomycin C therapy.
There were no infectious complications after the BCG
infusion. All patients treated with intravesical therapy
relapsed and ultimately required cystectomy. One patient
with T1 disease underwent radical cystectomy following
his initial TURBT, instead of local therapy. Radical cystec-
tomy or cystoprostatectomy was attempted in four
patients, and three patients had an orthotopic neobladder
created. One of these individuals was found to have
tumor adherent to the pelvic side wall and the procedure
was aborted. Two patients had external beam pelvic radi-
ation therapy for treatment of their bladder tumors. The
first received 5000 Gy over 28 days and did not respond
[2]. The second received 60 Gy complicated by radiation
CT scan of Case 1 Figure 1
CT scan of Case 1. large lobulated, enhancing soft tissue 
mass affecting the left side of the bladder (a).
CT scan of Case 1: bladder cancer mass with associated left  hydronephrosis and hydroureter Figure 2
CT scan of Case 1: bladder cancer mass with associ-
ated left hydronephrosis and hydroureter.
invasive high grade transitional cell carcinoma with neuroen- docrine features (H&E stain) Figure 3
invasive high grade transitional cell carcinoma with 
neuroendocrine features (H&E stain).BMC Urology 2009, 9:10 http://www.biomedcentral.com/1471-2490/9/10
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cystitis, genital inflammation and diarrhea, but was suc-
cessful at controlling the disease [3]. Three patients
received palliative radiation to the bladder and sites of
metastatic disease (brain and bone), complicated by hem-
orrhagic cystitis in two patients. One patient underwent
vesical artery embolization for palliation of recurrent
gross hematuria. Two patients were treated with systemic
therapy, including methotrexate/vinblastine/doxoru-
bicin/cisplatin (MVAC), gemcitabine/cisplatin, and gem-
citabine/carboplatin. Both of these patients developed
renal impairment and ultimately died from advanced and
progressive bladder cancer.
Patient Outcome
Several of the patients (6/11; 55%) were alive within four
months to one year after their case was reported. How-
ever, five (71%) of these individuals relapsed with local
disease (3 cases), in case 2 multiple times, or with metas-
tases (2 cases). Relapse in one patient (case 1) manifested
with symptoms mimicking pyelonephritis (acute cos-
tovertebral angle tenderness and infection on urinalysis).
However, a CT-urogram in this individual demonstrated a
large lobulated, enhancing soft tissue mass affecting the
left side of the bladder, and associated left hydronephrosis
and hydroureter (Figure 2). Subsequent cystoscopy iden-
tified a large volume of tumor, predominantly involving
the left lateral bladder wall that extended anteriorly and
across the trigone to the right side. A left obturator lymph
node excision in this patient showed metastatic carci-
noma and one month later he presented with diffuse ver-
tebral metastases. Case 2 was also hospitalized after
cystoprostatectomy for right ureteral colic and pyelone-
phritis and ultimately had a right nephrostomy tube
placed along with lithotripsy for recurrent stone disease.
The two patients with Ta tumors each initially underwent
TURBT, but both ultimately relapsed with superficial dis-
ease. Of the patients who had or developed T1 disease,
two survived without further disease, two relapsed with
superficial tumors and required cystectomy but survived,
and two relapsed with metastatic disease and died. Over-
all, four (36%) of these patients died, 3 as a result of their
bladder carcinoma and one (case 1) due to aspergillus
pneumonia. All patients died within 5-7 months of their
diagnosis of metastatic or locally invasive disease, except
for one person (case 4) who died 3 years after his initial
cancer diagnosis.
Discussion
In this study, we present the first series of HIV-associated
bladder cancer consisting of 11 patients compiled from
our case files and case reports from the literature. Based
upon only single case reports it has been difficult to deter-
mine if this NADC is associated with particular risk fac-
tors, clinical manifestations, pathology, biological
behavior, or management issues in the setting of HIV
infection. While studies to date have not been able to
demonstrate an increased incidence of bladder cancer in
the HIV population, we identified certain clinical factors
in this group of immunocompromised individuals which
may affect the diagnosis and management of bladder can-
cer [5].
There are approximately 68,000 new cases of bladder can-
cer diagnosed each year in the United States, with 75% of
cases occurring in men [12]. Our male-to-female ratio was
consistent with this trend. Bladder cancer is also typically
a disease of longevity, with the median age at diagnosis in
the general population reported to be around 73 years
[13]. The incidence of bladder cancer increases with age.
In our evaluated cases, the median age at diagnosis was
slightly younger at 55 years, and the oldest patient was 67
years. In the general (non-HIV infected) population in the
United States bladder cancer is more prevalent in Cauca-
sians than in African Americans and Hispanics. Our data
is insufficient to comment on the racial demographics of
HIV-associated bladder cancer.
Although the degree of immunosuppression has not
proven to be a major risk factor in the development of sev-
eral NADC, the duration of HIV infection appears to play
an important role in tumorigenesis [1]. In our study, 91%
of the patients were not markedly immunosuppressed at
the time of diagnosis of their bladder malignancy. The
median CD4+ cell count in our series was 280 cells/mm3
invasion of the urinary bladder muscularis propria and local  lymphatic vessels (H&E stain) Figure 4
invasion of the urinary bladder muscularis propria 
and local lymphatic vessels (H&E stain).BMC Urology 2009, 9:10 http://www.biomedcentral.com/1471-2490/9/10
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and the average duration of HIV infection was 8 years
prior to diagnosis of bladder cancer. Up to 55% of the
patients in our study were on HAART, and one patient was
on single agent zidovudine [3]. Two patients were started
on antiretroviral therapy at the time of cancer treatment,
one patient with HAART and one with zidovudine. Unfor-
tunately compliance data was not available for many of
these patients, but two were known to be noncompliant
with HAART.
Interrupted antiretroviral therapy has certainly been
linked to cancer development [14]. It is unclear if the
degree of non-compliance on antiretrovirals was related
to the bladder cancer in these patients. One patient (case
1), with a history of noncompliance with HAART, pre-
sented with hematuria after stopping his antiretrovirals
for three months. Although several of the patients from
the literature were diagnosed with HIV prior to the advent
of HAART, none of the patients in this series suffered from
significant HIV-associated co-morbidities, other than one
individual with Kaposi Sarcoma and oral candidiasis. One
patient, case 1, died of pulmonary Aspergillus infection.
Also, one patient (case 5) did have a history of cervical
cancer, but this was diagnosed decades prior to develop-
ing both HIV and bladder cancer. Most (80%) cases of
urothelial carcinoma in our study were high grade at pres-
entation. One individual developed carcinoma with neu-
roendocrine differentiation, which is a rare tumor with an
aggressive behavior. We did not observe an obvious asso-
ciation between the degree of HIV-related immunosup-
pression and adverse response to therapy.
The major risk factors for transitional cell cancer of the
bladder include tobacco use, exposure to chemicals (e.g.
arylamines and cyclophosphamide with long-term use),
and a history of pelvic radiation. Occupational risk factors
include recurrent and early exposure to hair dye, and
exposure to dye containing aniline, a chemical used in
medical and industrial dyes. Other potential risk factors
include chronic bladder inflammation (from recurrent
urinary tract infections and/or urinary stones), consump-
tion of Aristolochia fangchi (a herb used in some weight-
loss formulas), a diet high in saturated fat, and a family
history of bladder cancer. Several studies have indicated
that the HIV-infected population uses tobacco at an
increased rate as compared to the general population [15].
Over half the patients in our series consumed tobacco.
Occupational or other chemical exposures were not iden-
tified this cohort. HIV-infected patients who develop non-
Hodgkin lymphoma, are likely to be exposed to cyclo-
phosphamide as part of their chemotherapy regimen. The
risk of bladder cancer associated with cyclophosphamide
is related to the total dose of the medication received and
if the patient developed hemorrhagic cystitis. To date,
there is no known clear association between antiretroviral
medications and the development of bladder cancer. The
treatment of cervical cancer, prostate cancer and certain
lymphomas involving the pelvic lymph nodes, which can
occur with greater frequency in the HIV population, may
involve radiation of the pelvis. One of our patients had a
history of cervical cancer treated in this manner, resulting
in hemorrhagic cystitis and ultimately bladder cancer.
Recurrent bacterial infections of the urinary tract and a
history of Schistosoma haematobium infection may predis-
pose patients to the development of SCC of the urinary
bladder. Two of our patients suffered recurrent cystitis.
However, both of these patients developed TCC. The clin-
ical details about the patient with squamous cell carci-
noma from the literature were not reported. A possible
explanation for the younger age of onset of bladder cancer
in our group of HIV-infected patients is earlier, or poten-
tially more extensive, exposure to risk factors.
An interesting link between antiretroviral therapy and
bladder cancer involves antagonists to the CXCR4 recep-
tor. The CXCR4/CXCL12 axis appears crucial in the metas-
tasis of bladder cancer. CXCR4 is a chemokine receptor
present on human T-cell lymphocytes responsible for HIV
entry into the host cell. CXCR4 has also recently been
found to participate in the process of metastases of several
human tumors, including bladder cancer. One study dem-
onstrated high levels of CXCR4 expression in invasive and
locally advanced bladder cancer tissue samples, low levels
in superficial bladder tumor cells, and no expression in
normal urothelial cells [16]. Exposure of bladder cancer
cells expressing CXCR4 to CXCL12 (the cytokine known
as stromal cell-derived factor-1) leads to cell migration
and invasion of the extracellular matrix. Moreover, the
addition of 4F-benzoyl-TE14011, a CXCR4 antagonist, to
the environment reduces tumor cell invasion [17]. Cur-
rently, there are no approved CXCR4 antagonists for use
in humans. However, based on the aforementioned pub-
lished data the CXCR4/CXCL12 pathway is a promising
target for the treatment of bladder cancer.
Initial symptoms of bladder cancer may include painless
hematuria, infection, and urinary obstruction if the tumor
is near ureteric orifices. Hematuria is the most common
presenting symptom of bladder cancer, although its pres-
ence is nonspecific. Characteristically, hematuria in this
setting is grossly apparent and may involve blood clots, is
present throughout the urine stream, and is painless. All
but one of the patients in our series with a recorded clini-
cal history presented with hematuria. Constitutional
symptoms including weight loss are infrequent, and typi-
cally associated with more advanced bladder cancer. Sev-
eral of the patients reported symptoms of bladder
irritation such as urinary frequency or urgency. Dysuria,
and lower abdominal and pelvic pain were also present.
Necrotic tissue within the bladder in several of cases mayBMC Urology 2009, 9:10 http://www.biomedcentral.com/1471-2490/9/10
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have become secondarily infected. The evaluation of any
of the above signs and symptoms (dysuria, frequency,
urgency and even hematuria) in patients infected with
HIV involves a wide differential, which can lead to a delay
in diagnosis of bladder cancer. One patient in our series
initially presented with microscopic hematuria on routine
urinalysis. Ultrasound at that time demonstrated bilateral
nephrolithiasis and urine cytology was negative. One year
later, he had gross hematuria and was diagnosed with
bladder cancer. He had an aggressive tumor and ulti-
mately died of metastatic bladder cancer.
Infection-related cystitis is probably the most common
etiology for dysuria, hematuria, urinary urgency and fre-
quency. Other causes to consider include stones (kidney
and bladder), renal disease, medications (e.g., rifampin),
urinary obstruction, trauma and in men over the age of 40
years benign prostatic hyperplasia (BPH). Immunosup-
pression and voiding dysfunction in HIV infected patients
have been linked to an increased incidence of urinary tract
infection in this population [18]. Sexually transmitted dis-
eases, including gonorrhea and chlamydia, can cause dys-
uria, especially in men. In addition, acute bacterial
prostatitis can present with dysuria and pelvic pain. An
important consideration in the AIDS population is the
potential for opportunistic and unusual infections. For
example,  Toxoplasma gondii can cause cystitis and even
manifest as a bladder tumor in HIV-infected patients [19].
Also, several case reports have linked HIV infection with
lower genitourinary tract condylomata from HPV infec-
tion [20]. Other opportunistic viral infections such as
cytomegalovirus, adenovirus, and BK virus can all cause
cystitis. BK virus specifically is an important cause of hem-
orrhagic cystitis and should be included in the differential
of an HIV infected patient presenting with hematuria [21].
Lastly,  Mycobacterium tuberculosis can lead to irritative
bladder symptoms, usually as a consequence of the organ-
ism migrating from a primary kidney infection [22]. Met-
abolic derangements associated with HIV and its
treatment can lead to dehydration and promote stone for-
mation [18]. The use of protease inhibitors, specifically
indinavir and recently atazanavir, is a well known cause of
nephrolithiasis [23]. One of our patients (case 2) suffered
from both recurrent bacterial cystitis and indinavir-related
bladder stones. Finally, a malignancy at any location
along the genitourinary tract can lead to hematuria, espe-
cially renal cell carcinoma. Several different forms of non-
Hodgkin lymphoma have been reported involving the uri-
nary tract. Primary T-cell lymphoma and B-cell lym-
phoma of the urethra have been diagnosed during the
evaluation of hematuria in HIV-infected patients [24,25].
Rare cases of Burkitt lymphoma and anaplastic large cell
lymphoma of the bladder have been reported in this pop-
ulation [26,27]. Given this extensive differential, hematu-
ria in a patient with HIV infection should lead to prompt
and thorough evaluation.
The diagnosis of bladder cancer includes urine cytology,
urological tests (e.g. cystoscopy and biopsy) and imaging
tests. Urine cytology and ultrasound were not helpful in
identifying malignancy in our cohort. CT scan, particu-
larly CT-urogram, did identify bladder wall thickening in
several patients. As expected, cystoscopy was most effec-
tive at identifying lesions and allowed for biopsy and
diagnosis at the same time. Staging, based on the depth of
invasion through the bladder wall, is the principle factor
in determining prognosis and management. Other prog-
nostic factors identified in some series include hydrone-
phrosis, anemia, expression of various proteins (e.g.
blood group substances, epidermal growth factor recep-
tor) and genetic abnormalities (e.g. aneuploidy, p53, Rb,
p21). This molecular information was not available in any
of these cases, but may be interesting to examine in future
studies. The majority of our patients (7/9; 78%) presented
at an early stage of bladder cancer without invasion of the
muscularis propria, and only one patient had metastatic
disease at diagnosis. This is consistent with the experience
in the general population, in which 75% of cases are diag-
nosed with localized disease [13]. As initial, and poten-
tially curative, therapy for early stage disease involves
surgery, all patients in this study underwent either partial
(TURBT) or complete resection of their tumors. After
TURBT for superficial disease, approximately 40-80%
patients will relapse and 10-25% of these cases will
involve invasive or metastatic disease. Indeed, five
patients in our series relapsed, three with superficial
tumors and two with metastatic disease. A single patient
had multiple relapses.
Intravesical immunotherapy or chemotherapy is standard
after TURBT to prevent relapse in high risk patients. Addi-
tionally, the goals of adjuvant intravesical therapy include
eradication of residual disease and prevention of disease
progression. Several agents have been used in this capac-
ity, however, immunotherapy with BCG has generally
proven more efficacious than chemotherapy. BCG has a
documented long-term progression free survival and
bladder cancer-specific survival [28]. The goal of BCG
administration is to create a local immune response
which has anti-tumor effect. This local immune response
includes the recruitment and activity of CD4+ T-helper
cells. Intravesical chemotherapy with mitomycin C is also
effective in the adjuvant setting. Three patients in our
series received intravesical mitomycin C or epirubicin fol-
lowing TURBT. Two of these patients recurred and
required cystectomy, and one recurred with metastatic dis-
ease and died.
As BCG is a live, attenuated strain of Mycobacterium bovis,
it is not typically used in immunosuppressed (including
HIV-infected) patients as there is a theoretical increased
risk of life-threatening disseminated infection. We are
aware of one case report that documented the develop-BMC Urology 2009, 9:10 http://www.biomedcentral.com/1471-2490/9/10
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ment of bilateral interstitial pneumonitis in an HIV-
infected patient after intravesical therapy with BCG [29].
Systemic M. bovis infection after intravesical administra-
tion is a rare occurrence in the general population, and is
typically responsive to antituberculosis therapy. One
study presented the uncomplicated use of intravesical
BCG in three renal transplant recipients. In that study, two
patients received prophylactic antituberculosis therapy
concurrently with their intravesical infusions, and none
developed systemic M. bovis infection [30]. Anecdotally,
intravesical BCG has been used safely in HIV infected
patients with bladder cancer. A single patient in our series
received an infusion of intravesical BCG in an effort to
prevent cystectomy, and he did not develop infectious
complications. In addition to the infection concerns,
intravesical BCG may be ineffective in patients with HIV.
Intravesical BCG is dependent on a functioning immune
system to exert its local effects. Due to the decrease in
CD4+ cells, BCG may not be able to sufficiently stimulate
the host immune system to create the necessary anti-
tumor activity in the HIV-infected patient. Given the risk
of disseminated infection and potential suboptimal
response to this therapy in HIV-infected patients, BCG
therapy should probably be used with caution or avoided
until further studies are performed. The inability to use
intravesical BCG in the management in bladder cancer,
however, underscores the importance of early detection in
this population.
Invasion of the muscularis propria is an indication for
radical cystectomy, as partial resection in this group of
individuals may lead to inferior results. A 2003 trial dem-
onstrated a survival benefit to neoadjuvant chemotherapy
for patients with muscle-invasive disease. The two
patients in this study who presented with muscle-invasive
disease received adjuvant cisplatin-based chemotherapy,
but both died within 6 months of diagnosis. Two addi-
tional patients developed metastatic disease and received
metastasis-specific treatment for palliation (whole brain
and bone radiation) without systemic chemotherapy and
died. In the Surveillance Epidemiology and End Result
(SEER) data for bladder cancer, the 5-year survival for
localized, regional and distant disease is 92.5%, 44.7%
and 6.1% respectively [13]. Our findings are consistent
with this data in that patients who had only superficial
disease, even with relapse, did well with resection and
local therapy, and those with regional or metastatic dis-
ease did poorly.
Conclusion
We present the largest series of HIV-associated bladder
cancer involving 11 patients. Bladder cancer is part of the
growing list of cancers likely to be encountered in HIV-
infected patients now living longer with controlled HIV
disease. Acknowledging the limitation of our small retro-
spective study with incomplete information in some of
the cases, these data suggest that such HIV-positive
patients with bladder cancer are likely to present at a
slightly younger age and with only mild immunosuppres-
sion. Hematuria, dysuria, frequency and/or urgency in an
HIV-infected patient warrants complete evaluation, and
the differential diagnosis should include bladder cancer.
Persistent urinary symptoms should be evaluated by a
specialist and special investigations including cystoscopy.
Most patients in our series presented with early stage dis-
ease, and despite their frequent relapses and development
of subsequent metastases, followed an expected course for
their bladder cancer. HIV-positive cigarette smokers and
those who chew tobacco should be counseled on the
potential risk of bladder malignancies. Finally, further
observation and investigation are needed to better under-
stand the natural history and appropriate treatment of
bladder cancer in the HIV-infected population.
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